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Objective: This study aimed to evaluate the perioperative and long-term outcomes associated with extrapleural
pneumonectomy for patients with malignant pleural mesothelioma.
Methods: From October 1994 to April 2008, 70 patients were selected for extrapleural pneumonectomy. Univar-
iate analysis was performed using the Kaplan–Meier method and compared using the log-rank test. Multivariate
analysis with entering and removing limits of P less than .10 and P greater than .05, respectively, was used. The
prognostic factors included age, gender, side of disease, asbestos exposure, histology, positron emission tomog-
raphy, date of surgery, neoadjuvant chemotherapy, completeness of cytoreduction, lymph node involvement,
perioperative morbidity, adjuvant radiotherapy, and pemetrexed-based chemotherapy.
Results: The mean age of patients was 55 years (standard deviation ¼ 10). Fifty-eight patients had epithelial
tumors. Six patients received neoadjuvant chemotherapy, 28 patients received adjuvant radiotherapy, and 16
patients received postoperative pemetrexed-based chemotherapy. Forty-four patients had no lymph node involve-
ment. The perioperative morbidity and mortality were 37% and 5.7%, respectively. Complications included
hemothorax (n ¼ 7), atrial fibrillation (n ¼ 6), empyema (n ¼ 4), bronchopulmonary fistula (n ¼ 3), right-sided
heart failure (n ¼ 2), pneumonia (n ¼ 1), constrictive pericarditis (n¼ 1), acute pulmonary edema (n¼ 1), small
bowel herniation (n ¼ 1), and disseminated intravascular coagulopathy (n ¼ 1). The median survival was 20
months, with a 3-year survival of 30%. Asbestos exposure, negative lymph node involvement, and receipt of
adjuvant radiation or postoperative pemetrexed-based chemotherapy were associated with improved survival
on both univariate and multivariate analyses.
Conclusion: The present study supports the use of extrapleural pneumonectomy-based multimodal therapy in
carefully selected patients with malignant pleural mesothelioma.Extrapleural pneumonectomy (EPP) is en bloc resection of
the disease involving the pleurae, lung, ipsilateral hemi-
diaphragm, and pericardium.1-6 It has been used as a treat-
ment option for selected patients with malignant pleural
mesothelioma (MPM).1,3,5,6 Recent evidence has suggested
that EPP in conjunction with chemotherapy and radiother-
apy may improve local disease control and survival, when
compared with historical data.6-9 However, the majority of
patients with MPM present with extensive disease and
poor performance status, precluding the possibility of under-
going an EPP.
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is macroscopic tumor eradication to prolong survival. In
contrast with pleurectomy with or without decortication,
EPP provides radical cytoreduction.10 However, the proce-
dure has been associated with relatively higher morbidity
and mortality, stressing the need for careful patient selec-
tion.11-13 In the current literature, there is still a paucity of
data on EPP for patients with MPM. On the basis of data
prospectively collected in a computerized database, we per-
formed an observational study on a cohort of 70 patients
with MPM to evaluate the perioperative and long-term
outcomes associated with EPP.
PATIENTS AND METHODS
Patient Selection
Between October 1994 and April 2008, 424 patients with a tissue diag-
nosis of MPM were treated by a thoracic surgical team led by the same sur-
geon (B.C.M.). Preoperative assessment included a review of all prior
clinical information, physical examination, serum chemistry and hematol-
ogy, chest x-ray, computed tomography of the chest, and upper abdomen
and pulmonary function testing. Since the year 2000, positron emission to-
mography (PET) became available at our institution, The Royal Prince
Alfred Hospital, Sydney, Australia. Patients with extrathoracic spread based
on PET scan were considered inappropriate for EPP. The criteria for EPP
were as follows: extent of disease limited to the ipsilateral hemithoraxardiovascular Surgery c Volume 138, Number 3 619
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EPP ¼ extrapleural pneumonectomy
MPM ¼ malignant pleural mesothelioma
PET ¼ positron emission tomography
with no transdiaphragmatic, transpericardial, or extensive chest wall in-
volvement; good performance status (World Health Organization Perfor-
mance Status  2); normal renal and liver function test results; and
adequate cardiac (ejection fraction>50%, based on preoperative echocar-
diogram) and pulmonary function (forced expiratory volume in 1 second>
70% and vital capacity>3 L) assessment. Informed consent was obtained
from all patients before surgery. On the basis of the assessment described
below, 70 patients (16%) were selected for EPP and are included in this
study’s analysis. Six patients (9%) received preoperative pemetrexed com-
bined with cisplatin or carboplatin before EPP.
Pleurectomy/decortication was reserved for patients with insufficient
cardiopulmonary reserve, advanced age, anatomic constraints, or only
limited disease. In patients who were not candidates for EPP or pleurec-
tomy/decortication, palliative pleurodesis was performed via a thoracotomy
or thoracoscopic technique, and talc was instilled to cause sterile pleural
inflammation and subsequent obliteration of the pleural space. Of these
424 patients, 70 patients (16%) underwent EPP, 177 (42%) underwent
pleurectomy or decortication and the remaining 177 (42%) had pleurodesis
or biopsy.
Operative Techniques
EPP was performed with en bloc resection of the lung, pleurae, ipsilateral
hemidiaphragm, and pericardium. EPP was approached from an extended
posterolateral thoracotomy incision at the entire costal surface of the lung
and extending over the apex of the pleura, mobilizing mediastinal pleura
down to the hilum. The main pulmonary vessels were ligated and divided
separately, and the bronchus was stapled. On control of these structures,
the dissection was carried anteriorly by entering the pericardium, and the re-
section of the pericardium and hemidiaphragm was performed en bloc with
the lung and parietal pleura. Systematic mediastinal lymph node dissection
was routinely performed, and the specimens were submitted for histologic
examination. The pericardial and diaphragmatic defects were repaired
with 2-mm polytetrafluoroethylene (Gore-Tex; WL Gore & Associates,
Inc, Flagstaff, Ariz) dual mesh.
Adjuvant Therapy
Adjuvant radiotherapy after EPP was introduced in 2002 in an attempt to
improve locoregional disease control.8,9 Patients were referred to a radiation
oncologist for assessment within 6 weeks of surgery. Selection criteria for
radiotherapy include good performance status, adequate residual cardiopul-
monary function, and satisfactory recovery from surgery. Radiotherapy
would commence within 12 weeks of surgery after mediastinal shift settled
and patients had recovered from surgery. In most of the patients, a 4-beam
mixed photon and electron technique was used, delivering a total dose of 45
Gy in 25 daily fractions with 9 Gy boost to the entire hemithorax, ipsilateral
mediastinum bed, and ipsilateral chest wall. Chemotherapy was not rou-
tinely used as an adjuvant therapy. However, in recent years some evidence
suggested that pemetrexed plus cisplatin or carboplatin resulted in superior
survival time.14-16 In the present study cohort, a proportion of patients
received postoperative pemetrexed combined with cisplatin or carboplatin.
Data Analysis
The chairperson of the ethics committee approved the current study and
waived the need for patient consent because individual patients were
not identified. Patient characteristics and clinical data were recorded in620 The Journal of Thoracic and Cardiovascular Sua prospective electronic database. All tissue specimens were submitted for
histopathologic examination. The current International Union Against
Cancer staging identifies metastases in the ipsilateral bronchopulmonary
or hilar lymph nodes as N1 and metastases in the subcarinal or ipsilateral
mediastinal lymph nodes, including the ipsilateral internal thoracic artery
nodes, as N2, whereas diaphragmatic nodes are not specifically consid-
ered.17 Patients were followed postoperatively with clinical examination
and chest computed tomography scan every 3 months for the first year
and every 6 months thereafter until the last time of contact or death.
In this study, overall survival was used as the primary end point,
which was determined from the time of surgery. The statistical analyses
of 13 potential prognostic factors were performed. These prognostic factors
included age, gender,11,18 left side versus right of disease,11 prior asbestos
exposure,11,19 histopathologic subtype,20 whether preoperative PET was
performed, date of surgery, neoadjuvant chemotherapy, complete versus
incomplete macroscopic cytoreduction,20 presence versus absence of lymph
nodes,18,20,21 presence versus absence of perioperative morbidity, and
whether postoperative radiotherapy8 or pemetrexed-based chemotherapy
regimens14 were given. The reasons for including these variables in the
data analysis are because they have been found to have significant prognos-
tic values in other studies (as referenced above) or they may have potential
clinical implications for future patient management (eg, PET, neoadjuvant
chemotherapy,22,23 perioperative morbidity, and adjuvant therapies8). Sur-
vival analysis included perioperative deaths. Secondary end points were
perioperative morbidity and mortality. Hospital mortality was defined as
any death that occurred during the same hospital admission or within
30 days after surgery. Survival analysis was performed using the Kaplan–
Meier method and compared using the log-rank test. For multivariate anal-
ysis, a Cox regression (Cox proportional hazards model) was used with
a forward stepwise selection of covariates and with entering and removing
limits of P less than .10 and P greater than .05, respectively. Statistical anal-
yses were performed by the intention-to-treat principle, using the Statistical
Package for the Social Sciences for Windows (Version 14.5; SPSS GmbH,
Munich, Germany).
Patient Characteristics
Between October 1994 and April 2008, 70 patients with MPM were
judged preoperatively to be candidates for EPP. The follow-up of these
70 patients was complete, with a median follow-up of 13 months (range
0–104 months). By each 3-year interval, 3, 11, 9, 21, and 26 patients
were treated during the study period. The mean age at the time of EPP
was 55 years (standard deviation ¼ 10). Fifty-five patients (79%) were
male. Forty-eight patients (69%) reported to have prior asbestos exposure.
Fifty-eight patients (83%) had epithelial tumors, and 12 patients (17%)
had biphasic or sarcomatoid tumors. Thirty-two patients (46%) had left-
sided EPP, and 38 patients (54%) had right-sided EPP. Forty-five patients
(64%) had preoperative PET. Sixty-three patients (90%) had complete
macroscopic cytoreduction, and the remaining 7 patients (10%) had resid-
ual macroscopic disease at the end of surgery. The incomplete resection
sites included the chest wall (n ¼ 3), superior mediastinum (n ¼ 1), aortic
arch (n¼ 1), pericardium (n¼ 1), and esophagus (n¼ 1). Six patients (9%)
underwent neoadjuvant chemotherapy (pemetrexed combined with cisplatin
or carboplatin). Postoperatively, 28 patients (40%) received adjuvant ipsilat-
eral radiotherapy and 16 patients (23%) received pemetrexed combined with
cisplatin or carboplatin. Eleven patients (16%) received more than 1 adjuvant
therapy, including 1 patient who received neoadjuvant chemotherapy, adju-
vant radiotherapy, and pemetrexed combination chemotherapy; 6 patients
received adjuvant radiotherapy and pemetrexed combination chemotherapy;
2 patients received neoadjuvant chemotherapy and adjuvant radiotherapy;
and the remaining 2 patients received neoadjuvant chemotherapy and
pemetrexed combination adjuvant chemotherapy.
Forty-four patients (63%) had no lymph node involvement (N0).
Nineteen patients (27%) had 1 lymph node station involved. This included
9 patients with N1 (6 ipsilateral bronchopulmonary and 3 hilar) and 10rgery c September 2009
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(7 subcarinal, 2 superior mediastinal, and 1 diaphragmatic) but N1 nodes
were negative. The remaining 7 patients (10%) had more than 1 lymph
node station involved (both N1 and N2 involved: 5 ipsilateral bronchopulmo-
nary, 4 hilar, 7 subcarinal, 3 superior mediastinal, and 3 inferior mediastinal).
RESULTS
Morbidity and Mortality Data
Twenty-six patients (37%) experienced 1 or more perio-
perative complications. These adverse events included
hemothorax (n ¼ 7), atrial fibrillation (n ¼ 6), empyema
(n¼ 4), bronchopleural fistula (n¼ 3), right-sided heart fail-
ure (n¼ 2), aspiration pneumonia (n ¼ 1), constrictive peri-
carditis (n ¼ 1), acute post-pneumonectomy pulmonary
edema (n ¼ 1), small bowel herniation through chest wall
(n¼ 1), and disseminated intravascular coagulopathy (n ¼ 1).
Four patients (5.7%) died perioperatively. One patient died
of intrathoracic hemorrhage secondary to disseminated
intravascular coagulopathy; 1 patient died of acute coronary
embolus causing ventricular fibrillation; 1 patient died of
post-pneumonectomy acute pulmonary edema; and 1 patient
had a sudden death, the cause of which was undetermined
even at postmortem.
Survival Data
The median survival was 20 months (range 0–104
months), with 1-, 2-, 3-, and 5-year survivals of 62%,
41%, 30%, and 15%, respectively (Figure 1). Twenty-six
patients (37%) remained alive at the last follow-up.
Four clinicopathologic factors were found to be associated
with an improved overall survival on univariate analysis:
prior asbestos exposure (P ¼ .002), absence of lymph node
involvement (P ¼ .020), adjuvant radiotherapy (P ¼ .001),
and postoperative pemetrexed combined with cisplatin or
carboplatin (P ¼ .010) (Table 1). The same 4 factors were
also independently associated with an improved survival
on the multivariate analysis: prior asbestos exposure (P ¼
.021), absence of lymph node involvement (P¼ .033), adju-
vant radiotherapy (P¼ .047), and postoperative pemetrexed
and cisplatin or carboplatin (P ¼ .019) (Table 2).
Age at the time of surgery (P ¼ .431), gender (P ¼ .266),
side of disease (P ¼ .449), histopathologic subtype (P ¼
.069), PET scan (P¼ .062), date of surgery (P¼ .234), neo-
adjuvant chemotherapy (P ¼ .481), macroscopic complete
cytoreduction (P ¼ .920), and perioperative morbidity
(P ¼ .479) were not significant prognostic indicators for
overall survival in the present series (Table 1).
Subgroup analyses demonstrated that skip lymph nodal
metastases (7 ipsilateral subcarinal, 2 superior mediastinal,
and 1 diaphragmatic) were associated with a better survival
when compared with other N2 categories (median survival:
21 vs 7 months, P ¼ .015), and that survival for these
patients was not significantly different from that of patients
with N1 disease (P ¼ .468).The Journal of Thoracic and CDISCUSSION
Despite recent advances in surgical techniques and perio-
perative management, EPP remains a major challenge for
general thoracic surgeons. It is technically more complex
than pleurectomy and decortication, with a higher risk of
perioperative complications and death.24 Although it is gen-
erally accepted that palliative pleurodesis, pleurectomy, and
decortication are justified for the control of pleural effusion
and relief of respiratory symptoms in patients with MPM,
EPP is seldom performed in general thoracic centers. Recent
series have suggested that EPP may offer some promise to
patients with this debilitating disease. However, the benefits
of this radical surgical approach must be evaluated in terms
of the risk it presents. In the current literature, the overall
mortality associated with EPP alone or in conjunction with
chemotherapy or radiotherapy varies from 4% to 13%,
and morbidity ranges from 20% to 60%.2,3,11-13,24
Early series reported relatively high morbidity and
mortality results. In 1976, Butchart and colleagues1 reported
perioperative morbidity and mortality of 45% and 31%,
respectively, in 29 patients who underwent EPP. In 1989,
Ruffie and collaborators3 conducted a multi-institutional
registry study of 332 patients with MPM over a 20-year
period. Although the study lacks the technologic advances
available today, it provided a historic control against which
many modern studies can be compared. Of the 23 patients
who underwent EPP, the operative mortality was 13% and
major perioperative morbidity was 26%.3 Branscheid and
coworkers2 reported a perioperative mortality of 12% in
76 patients with MPM who underwent EPP. Several
tertiary referral centers with a high volume of experience
in EPP have reported improved perioperative outcomes
through accumulated experience in recent years. Flores
and colleagues11 demonstrated a perioperative mortality
of 5.3% for EPP (n ¼ 11/208). Sugarbaker and
FIGURE 1. Overall survival after extrapleural pneumonectomy for MPM
at the Royal Prince Alfred Hospital in Sydney, Australia (n ¼ 70).ardiovascular Surgery c Volume 138, Number 3 621
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Survival%
Variable Patients n Median survival (mo) 1 y 3 y P
Total 70 20 62 30 —
Age at the time of surgery — — — — .431
55 y 31 21 69 67 —
>55 y 39 14 58 37 —
Gender — — — — .266
Male 55 20 62 27 —
Female 15 27 61 41 —
Side of disease — — — — .449
Left 32 23 59 39 —
Right 38 19 66 19 —
Prior asbestos exposure — — — — .002
Yes 48 28 68 43 —
No 32 12 50 10 —
Histopathologic subtype — — — — .069
Epithelial 58 23 63 36 —
Sarcomatoid/biphasic 12 14 58 0 —
PET — — — — .062
Performed 45 26 65 43 —
Not performed 25 14 56 17 —
Time of operation — — — — .234
Before October 2003 35 19 63 22 —
After October 2003 35 NR 62 50 —
Neoadjuvant chemotherapy — — — — .481
Yes 6 21 100 33 —
No 64 19 59 30 —
Macroscopic complete cytoreduction — — — — .920
Complete cytoreduction 63 21 62 30 —
Incomplete cytoreduction 7 19 53 27 —
Lymph node involvement — — — — .020
No lymph node involvement 44 24 70 36 —
1 lymph node station involvement 19 19 58 20 —
>1 lymph node station involvement 7 7 0 0 —
Perioperative morbidity — — — — .479
Yes 44 21 66 32 —
No 26 19 56 27 —
Adjuvant radiotherapy — — — — .001
Performed 28 90 76 62 —
Not performed 42 14 53 17 —
Pemetrexedþcisplatin or carboplatin — — — — .010
Performed 16 60 92 68 —
Not performed 54 14 54 16 —
PET, Positron emission tomography.colleagues12 reported that 11 of 328 patients died perioper-
atively, for an overall mortality of 3.4%. The overall minor
and major morbidity rate was 60.4%.12
In our current study, the causes of perioperative death
were different in all 4 cases. One patient died of ipsilateral
intrathoracic bleeding and disseminated intravascular coa-
gulopathy on postoperative day 7. Acute respiratory failure
developed in 1 patient on postoperative day 1; the patient re-
quired endotracheal intubation and died on postoperative
day 2 of acute coronary embolus causing fatal ventricular
fibrillatory arrest. Acute pulmonary edema developed in622 The Journal of Thoracic and Cardiovascular Sur1 patient on postoperative day 2; despite urgent reintubation,
reopening thoracotomy, further patching of pericardium,
and establishment of extracorporeal membrane oxygenation,
the patient died. The cause of death for the fourth patient
was probably sepsis, but postmortem autopsy examination
was inconclusive. A perioperative mortality rate of 5.7%
and an overall morbidity rate of 37% seem to be within
the acceptable range.
The survival of patients with MPM with best supportive
care or nonsurgical therapy is variable. A recent multicenter
randomized trial demonstrated a median survival of 7.6gery c September 2009
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group compared with 8.5 months in the group with chemother-
apy.25 To evaluate the role of EPP, it is necessary to investigate
long-term survival in addition to perioperative safety. In this
study, the median survival was 20 months, with a 3-year
survival of 30%. These results support the benefit of EPP in
selected patients with MPM. Four clinicopathologic factors
were found to be significant for overall survival in multivariate
analysis: prior asbestos exposure, absence of lymph node
involvement, adjuvant radiotherapy, and postoperative peme-
trexed combined with cisplatin or carboplatin.
The lymphatic drainage from the visceral pleura generally
follows the ipsilateral bronchopulmonary or hilar nodes to
the subcarinal or mediastinal lymph nodes.17,21 The drainage
pattern of the parietal pleura may not flow to the bronchopul-
monary or hilar nodes but may pass through those along the
internal thoracic artery or diaphragm to the subcarinal or
mediastinal lymph node stations.17,21 Skip metastases,
where N2 nodes are involved but N1 nodes are spared,
have not been characterized in MPM as they have in non–
small cell lung cancer, in which they might correlate with
a better prognosis than other N2 categories.
26 The current
International Union Against Cancer staging identifies the
subcarinal or ipsilateral mediastinal lymph nodes, including
internal thoracic artery nodes, as N2.
17 It has been hypothe-
sized that some N2 nodes are involved earlier or more fre-
quently in MPM, because the tumor arises in the parietal
pleura and their involvement may not confer a poorer out-
come.17 However, because of the limited numbers of
patients with N1 disease alone or skip lymph nodal metasta-
ses in published studies, a statistical difference between the
2 groups has not been demonstrated.21,27 In the present
study, the subgroup analyses demonstrated that skip metas-
tases were associated with better survival compared with
other N2 categories and that the survival for patients with
skip metastases was similar to that of patients with N1 dis-
ease. Although this finding is significant, its interpretation
is limited by the small number of cases and subjectivity in
lymph node evaluation by different pathologists. It is possi-
ble that some of the patients classified as having skip
node metastases were inaccurately staged, that is, there
TABLE 2. Multivariate analysis of prognostic factors for overall
survival after extrapleural pneumonectomy for malignant pleural
mesothelioma
Multivariate analysis
Prognostic factor HR 95% CI P
Prior asbestos exposure 5.330 0.204–0.878 .021
Lymph node involvement – – .033
No vs 1 lymph node station 0.598 0.645–2.750 .439
No vs>1 lymph node stations 7.985 1.634–15.088 .005
Adjuvant radiotherapy 3.954 0.204–0.989 .047
Pemetrexed chemotherapy 5.497 0.153–0.846 .019
HR, Hazard ratio; CI, confidence interval.The Journal of Thoracic and Cwere positive N1 nodes that were missed or the diagnosis
of N2 pathology represented a false positive. The latter
would falsely elevate the reported survival of patients with
reported N2 skip metastases. Nevertheless, all patients in
the present study were surgically managed in a uniform
manner and had systematic lymph node dissection, which
provides meaningful information about the patterns of
lymph node spread. These observations on the differential
influence of skip metastases suggest that the potential impli-
cations of N1 versus N2 metastases in MPM should be care-
fully examined in future confirmatory multicenter studies.
Clear resection margins are difficult to obtain in EPP,
and this may contribute to the locoregional treatment fail-
ure.5 Recognizing that surgery alone may not provide
adequate local disease control has led to the development
of multimodality approaches involving surgery followed
by chemotherapy or radiotherapy.7-9 A direct comparison
of the multimodality therapy with other treatment ap-
proaches has not yet been published in the literature. Rusch
and colleagues8 demonstrated that adjuvant radiation, ad-
ministered to the entire ipsilateral hemithorax at a high total
dose after EPP, is feasible with acceptable toxicity and
that this treatment regimen is associated with a low risk of
local recurrence. The overall median survival for their
entire group of 61 patients was 17 months with a 3-year sur-
vival of 27%.8 On the basis of the encouraging results
from this study, adjuvant radiotherapy after EPP was intro-
duced in 2002 at our institution, The Royal Prince Alfred
Hospital, Sydney, Australia. Patients who had a good
performance status, an adequate residual cardiopulmonary
function, and a satisfactory recovery from surgery were
considered for adjuvant radiotherapy. The present study
demonstrated that adjuvant radiotherapy was independently
associated with an improved survival. However, given that
postoperative adjuvant therapy was only used after 2002,
the superior survival outcome may also be associated with
improved surgical technique or better case selection over
the years.
Until recently, chemotherapy has not been commonly
accepted as standard treatment for MPM. Vogelzang and
colleagues14 reported the largest trial in patients with unresect-
able MPM and demonstrated that combination chemotherapy
(pemetrexed plus cisplatin) achieved an improved survival,
time to progression, and response rates compared with
cisplatin alone (median survival time 12.1 vs 9.3 months;
log-rankP¼ .020; hazard ratio 0.77). Carboplatin, a platinum
analog that is better tolerated and easier to administer, pro-
duced similar response rates in a few phase II studies.15 In
recent years, our patients with MPM also received pemetrexed
plus cisplatin or carboplatin after EPP. The combination
chemotherapy was also independently associated with an
improved survival on the multivariate analysis.
Many studies have demonstrated that patients with epithe-
lial histologic subtype have an improved survival comparedardiovascular Surgery c Volume 138, Number 3 623
G
T
S
General Thoracic Surgery Yan et alwith patients with non-epithelial tumors. This survival dif-
ference was not demonstrated in our current report. This
may be partly due to the small numbers of patients with sar-
comatoid and biphasic tumors in our series. The histologic
subtype alone was not a patient selection criterion. However,
because patients with non-epithelial tumors are generally
more likely to have extensive disease, they are more likely
not to be candidates for EPP.
The main limitation of the present study is that the data
were nonrandomized; thus, unknown confounders may exist
that influenced the outcome. In addition, the inherent pres-
ence of selection bias and the timing factor may account
for the apparent improved survival in patients who received
adjuvant radiotherapy and combination chemotherapy. It is
possible that the improved survival in the present study com-
pared with historic controls reflects a ‘‘lead-time bias,’’
where patients underwent surgery earlier in their natural
course of disease as a result of early diagnosis and prompt re-
ferral. This might be related to modern diagnostic technolo-
gies and increased awareness of surgical treatment options
for MPM in the recent years. Nevertheless, these results
should encourage early diagnosis and treatment for MPM.
Although multivariate analysis has helped to identify 4 prog-
nostic factors, the true significance of each factor is difficult
to assess when interrelated factors are entered into the analy-
sis, and one must bear in mind the limitation of this method-
ology when interpreting the results. Over the years there has
been an evolution of treatment strategies, which included
addition of adjuvant radiotherapy, pemetrexed combination
chemotherapy, familiarity with surgical procedures, and bet-
ter imaging modalities. All of these factors may have contrib-
uted to the improvement in survival in this study compared
with historic controls. Prospective studies are needed to eval-
uate the role of adjuvant therapy in the treatment of MPM.
CONCLUSIONS
The present study demonstrated a perioperative mortality
of 5.7% and an overall morbidity of 37% in 70 patients with
MPM who underwent EPP at a high-volume center. The me-
dian survival time was 20 months, with a 3-year survival of
30%. These results support the use of EPP in carefully
selected patients with MPM. Negative lymph node in-
volvement and adjuvant radiotherapy or combination che-
motherapy were associated with an improved survival.
Although this preliminary information is encouraging, the
potential benefit of various types of adjuvant therapy should
be systematically explored in prospective clinical trials. The
main value of this experience is to provide a benchmark
against which the results of clinical trials can be judged.
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